



WEDNESDAY, 7th DECEMBER 2016 COMMENCING 9:30 AM
AT THE [PARK INN HOTEL CARDIFF NORTH](#), CIRCLE WAY EAST
LLANEDEYRN, CARDIFF, CF23 9XF

AGENDA

- | | |
|--------------------------------|--------------|
| 1. Welcome and introduction | Enclosure |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/1216 |

To protect commercial confidentiality the following appraisals will be held in private

- | | |
|--|----------------------------|
| 5. Appraisal 1: Full Submission (PAS)
Fingolimod (Gilenya[®]) a single disease modifying therapy in highly active relapsing remitting multiple sclerosis for adult patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI | 2/AWMSG/1216
Appendices |
| 6. Appraisal 2: Instructed Appraisal (WPAS)
Isavuconazole (Cresemba[®]) for the treatment of invasive aspergillosis and mucormycosis in patients for whom amphotericin B is inappropriate | 3/AWMSG/1216
Appendices |
| 7. Appraisal 3: Limited Submission (WPAS)
Ivacaftor (Kalydeco[®]) for the treatment of cystic fibrosis in children aged 2 to less than 6 years weighing less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R | 4/AWMSG/1216
Appendices |

The meeting will now open to the public (approximately 11.30am)

- | | |
|---|--------------|
| 8. Chairman's report (verbal update) | |
| 9. Educational Pack: Material to Support Appropriate Prescribing of Hypnotics and Anxiolytics across Wales | 5/AWMSG/1216 |
| 10. Therapeutic Priorities and Clinical Effectiveness Prescribing Programme Summary 2017–2018 | 6/AWMSG/1216 |

- | | | |
|-----|--|-----------------------------------|
| 11. | Dry Eye Syndrome Guidance | 7/AWMSG/1216 |
| 12 | Appraisal 4 – Full Submission
Ferric maltol (Feraccru®) for the treatment of iron deficiency anaemia in adults with inflammatory bowel disease | 8/AWMSG/1216
Appendices |
| 13. | Appraisal 5: Limited Submission
Adalimumab (Humira®) for the treatment of moderately active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies | 9/AWMSG/1216
Appendices |

Date of next meeting – Wednesday 15th February 2017 in Cardiff